[CLSTR]
< Back to situations

[ORGANIZATION]

Merck

Featured in 26 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [CD] [UG] [US]

DRC Ebola outbreak expands and impacts healthcare workers

407 clusters · 3144 sources · last updated

Latest: Ebola outbreak in DR Congo impacts women and girls disproportionately

The Bundibugyo-strain Ebola outbreak in the Democratic Republic of Congo (DRC) continues to escalate, marking the fastest-growing and deadliest epidemic in the country’s history. As of mid-September 2026, confirmed cases

[ACTIVE] [BUSINESS] [US]

Tempus AI earnings, Personalis acquisition, and pricing news

6 clusters · 10 sources · last updated

Latest: Tempus AI shares surge on planned diagnostic price increases

In early August 2026, Tempus AI reported a 22% year-over-year increase in second-quarter revenue to $382.5 million, driven by growth in diagnostics and data-applications. While the company posted its first quarterly prof

[ACTIVE] [HEALTH] [CL] [IT] [MX]

Head and neck cancer diagnostic challenges

2 clusters · 6 sources · last updated

Latest: Nasopharyngeal cancer: Early warning signs and Italian statistics

Medical reports highlight the diagnostic challenges and symptom profiles associated with various head and neck cancers. Head and neck cancers, including tumors of the oral cavity, pharynx, larynx, and salivary glands, of

[ACTIVE] [HEALTH] [IT] [US]

Advancements in cancer immunotherapy and vaccines

2 clusters · 4 sources · last updated

Latest: Cancer vaccine progress faces threat from disinformation

Advancements in cancer immunotherapy have focused on two primary areas: the development of lab-grown T-cells from hematopoietic stem cells and the use of personalized mRNA vaccines. The stem cell platform aims to provide

[ACTIVE] [HEALTH] [US] [ES]

Moderna and Merck melanoma vaccine clinical trials

9 clusters · 443 sources · last updated

Latest: Moderna reports positive Phase III results for personalized cancer vaccine

Moderna and Merck (MSD) have reported positive Phase 3 clinical trial results for intismeran autogene (also known as V940 or mRNA-4157), an experimental personalized mRNA cancer vaccine. The therapy is designed to target

[ACTIVE] [HEALTH] [CD] [UG] [FR]

DR Congo Ebola outbreak intensifies and spreads

11 clusters · 409 sources · last updated

Latest: DR Congo Ebola outbreak exceeds 7,200 cases and 3,500 deaths

The Bundibugyo Ebola outbreak in the Democratic Republic of Congo has become the deadliest in the nation’s history. As of mid-September 2026, official data from the National Institute of Public Health (INSP) indicated th

[QUIET] [HEALTH] [CA] [NO]

Advancements in RNA therapeutic technologies

3 clusters · 15 sources · last updated

Latest: RNA research advances potential treatments for genetic diseases

Developments in RNA technology are expanding from messenger RNA (mRNA) applications toward new therapeutic frontiers, including transfer RNA (tRNA). In oncology, personalized mRNA cancer vaccines are being tested in co

[QUIET] [HEALTH] [US] [IN]

Gilead Sciences HIV treatment developments

2 clusters · 4 sources · last updated

Latest: Gilead Sciences receives FDA approval for new once-daily HIV pill

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo, a once-daily single-pill HIV treatment. The medication combines bictegravir and lenacapavir to assist adult patients who have suppressed

[QUIET] [HEALTH] [BR]

2 clusters · 8 sources · last updated

Latest: Health training and research symposiums announced in Brazil

Also covered in